FindMyKOL
Clinical trialNCT00561756CompletedPhase 1Interventional

Vaccine Therapy in Treating Patients With Recurrent B-Cell Lymphoma

NCT00561756 is a phase 1 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. As of 21 Nov 2026, it is completed. It studies Plasmid DNA vaccine therapy in Lymphoma. The registry lists an enrollment of 8 participants at 1 site in 1 country. The registry lists a start date of 31 Oct 2007 and a primary completion date of 30 Nov 2015. One of its registered investigators has a FindMyKOL profile.

View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT00561756
FieldValue
Registry IDNCT00561756
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorMemorial Sloan Kettering Cancer Center
Enrollment8
Registered sites1
Countries1
ConditionsLymphoma
DrugsPlasmid DNA vaccine therapy
Start31 Oct 2007
Primary completion30 Nov 2015
Study completion30 Nov 2015
Last update posted17 Nov 2015

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Vaccines made from mouse DNA may help the body build an effective immune response to kill cancer cells. PURPOSE: This phase I trial is studying the side effects and best dose of mouse DNA vaccine in treating patients with recurrent B-cell lymphoma.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

New York, United States1 site
  • Memorial Sloan-Kettering Cancer Center

    New York

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew York: 1 siteNY1MassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Plasmid DNA vaccine therapy
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT00561756

Each answer restates registry values shown on this page.

What is NCT00561756?

NCT00561756 is a phase 1 interventional trial sponsored by Memorial Sloan Kettering Cancer Center. It studies Plasmid DNA vaccine therapy in Lymphoma.

Who leads NCT00561756?

The registry names Alan N. Houghton, MD (principal investigator, Memorial Sloan Kettering Cancer Center), Andrew D. Zelenetz, MD, PhD (principal investigator, Memorial Sloan Kettering Cancer Center) and M. Lia Palomba, MD (principal investigator, Memorial Sloan Kettering Cancer Center) as overall officials.

Where does NCT00561756 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT00561756 study?

The registered drug and biological interventions are Plasmid DNA vaccine therapy.

When did NCT00561756 end?

The registry lists a primary completion date of 30 Nov 2015 and a study completion date of 30 Nov 2015. The sponsor last updated the record on 17 Nov 2015.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.